Market Overview
The
Global Generative Al in Biology Market is expected to reach a value of
USD 92.1 million in 2023, and it is further anticipated to reach a market value of
USD 406.6 million by 2032 at a
CAGR of 17.9%.
Generative artificial intelligence (AI) in biology includes ML models capable of crafting realistic artifacts, not just predicting or classifying, which allows the creation of synthetic biological data mirroring real datasets, assisting researchers in exploring biological phenomena virtually, which includes generating genome sequences, cellular images, protein structures, & simulated expressions of genes and proteins. To allow the usefulness of these models, there's a need for evaluative benchmarks, allowing fidelity and use for downstream biologists.
Key Takeaways
- By Technology, Generative Adversarial Networks in 2023 & is anticipated to dominate throughout the forecasted period.
- In addition, Variational Autoencoders are expected to have significant growth over the forecasted period.
- By Application, Drug delivery & development takes the lead & drives the market in 2023.
- Further, By End User, Pharmaceutical & Biotechnology companies accounts for a major revenue share in 2023
- North America has a 40.2% share of revenue in Global Generative Al in Biology Market in 2023
Market Dynamic
The growth of generative AI in the biology market is driven by a growing focus on biomarker discovery. As important for understanding complex biological processes & diseases, biomarkers assist in developing targeted therapies. Generative AI assists this process by effectively analyzing large biological datasets, mainly crucial in personalized medicine. The availability of strong computational power & advanced infrastructure drives market growth, allowing specific AI models for insightful biological analyses.
However, the growth of generative AI in biology faces challenges due to Data security & privacy concerns, mainly in healthcare & pharmaceuticals, which hinder adoption. Also, compliance with regulations like HIPAA adds complexity. In addition, the reliability of AI-generated data creates a challenge, essential in high-stakes fields like drug discovery & medical imaging, where inaccurate data could lead to incorrect decisions.
Research Scope and Analysis
By Technology
The generative adversarial networks (GANs) segment in 2023 played a significant role in driving the global market, maintaining a major market share with expectations of sustained growth in the forecast period, which is linked to the growing adoption of GAN technology across different domains, like the creation of realistic images, presentation of protein structures, synthetic biology, & drug discovery. Further, GANs contribute to the growth of digital pathology, addressing image processing challenges like visual staining, color normalization, image enhancement, ink removal, nuclei segmentation, automatic feature extraction, & data augmentation.
Also, the variational autoencoders (VAEs) segment is expected to have noteworthy growth in the coming forecast period, with the growing use of VAE technology, mainly in modeling the underlying distribution of input data & generating new samples, providing significant opportunities for segmental growth in the market. Further, VAEs find applications in drug design, the generation of molecular structures, & the analysis of genomics data, highlighting their versatility & potential impact on advancing various fields.
By Application
Based on application, the drug discovery & development segment took the lead in the market in 2023 and is expected to maintain its dominance throughout the forecast period, as the integration of generative AI models & algorithms in drug discovery not only drives drug development but also reduces costs & enhances overall outcomes. Further, drug discovery stands as a complex & advanced process in the medical industry, generative AI proves to be a transformative force, supporting
Machine Learning ML to revolutionize the generation of novel medicinal solutions. Also, key applications like drug design optimization, molecule generation, and de novo drug design, showcase the vital role of generative AI in advancing drug discovery.
Further, the
medical imaging segment is expected to experience significant growth, driven by the important role of generative AI in the imaging process. Technologies like variational autoencoders & generative adversarial networks contribute to medical imaging by generating synthetic images, enhancing reconstructions, & assisting in treatment &disease diagnosis planning. The abundance of data produced in medical imaging necessitates expert analysis for extracting meaningful insights.
By End User
The pharmaceutical & biotechnology companies segment took the lead in the market in 2023, maintaining its dominance throughout the forecast period, as these companies generative AI for diverse applications like drug design, molecular interaction prediction, & the development of advanced therapeutic molecules. Generative AI vital role in data management & cloud computing within pharmaceutical & biotechnology processes, assisting in drug discovery, repurposing, customization, & expediting the overall drug development journey. Beyond drug discovery, it improves clinical trials & accurate medicine, contributing to advancements in healthcare.
Further, the healthcare provider segment is expected to experience notable growth in the forecast period, which is driven by the increasing integration of generative AI in healthcare infrastructure. The technology assists healthcare providers by facilitating early & correct disease identification, crafting personalized treatment plans, and providing virtual health assistance, like medication reminders. Its automation capabilities reduce patient care quality through personalized communication & preliminary triage diagnosis using chatbots.
The Generative Al in Biology Market Report is segmented on the basis of the following:
By Technology
- Generative Adversarial Networks
- Variational Autoencoders
- Reinforcement Learning
By Application
- Drug Discovery & Development
- Medical Imaging
- Genomics and Proteomics
- Protein Engineering
- Synthetic Biolog
By End User
- Pharmaceutical & Biotechnology Companies
- Healthcare Provider
- Research Institutions
Regional Analysis
North America led the generative AI in the biology market in 2023,
holding a substantial 40.2% share, as it is driven by its quick adoption of advanced technologies, mainly in healthcare & pharmacy. Further, the occurrence of diseases has grown with the demand for accountable & rapid solutions, driving the adoption of generative AI for faster drug discovery. Further, the region's strong R&D ecosystem, supported by prestigious universities & institutions, supports innovation and attracts top talent.
Moreover, Asia Pacific is expected for significant market growth. The region's growth in disease rates & population, along with the presence of major players developing AI-based platforms, create high expansion opportunities. Also, present collaborations and product launches with international partners further contribute to the region's burgeoning
generative AI market.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The global generative AI in biology market experiences a competitive landscape with various players competing for prominence. As major contributors like companies specializing in AI-driven drug discovery, synthetic biology, & genomic research. These entities compete to innovate & enhance the capabilities of generative AI in biological applications. Collaborations, strategic partnerships, & technological develop are instrumental in shaping the dynamic competitive environment, as organizations strive to lead in developing advanced solutions for the changing needs of the biology sector.
In September 2023, Generate Biomedicines secured USD 273 million in a recent funding round, with 25% of the total funding coming from new investors, while the remaining portion is contributed by existing investors like Abu Dhabi Investment Authority & Fidelity Management and Research Company.
Some of the prominent players in the global Generative Al in Biology Market are
- IBM Corp
- NVIDIA Corp
- DeepMind Technologies Ltd
- Zymergen
- Benevolent AI
- Insilico Medicine
- Recursion Pharmaceuticals
- Other Key Players
COVID-19 Pandemic & Recession: Impact on the Global Generative Al in Biology Market
The COVID-19 pandemic & following economic downturn have highly influenced the global generative AI in the biology market. While the pandemic highlighted the importance of advanced technologies in healthcare, like generative AI for drug discovery & medical research, the economic repercussions led to budget constraints, impacting market growth. The pharmaceutical & biotechnology sectors, major contributors to the generative AI market, experienced disruptions in R&D timelines. Despite the challenges, the pandemic has grown the adoption of generative AI in biology, mainly for virtual experimentation & drug design. As economies recover, there is a renewed emphasis on innovation, potentially driving increased investment in generative AI solutions for advancing research and development efforts in the life sciences.
Recent Developments
- In September 2023, U.S. chip company Nvidia announced a collaboration in Artificial Intelligence (AI) with India's Tata Group & conglomerate Reliance Industries, which aims to jointly develop language models, cloud infrastructure, & generative applications, reflecting a strategic alliance between these entities in advancing AI technologies.
- In June 2023, Insilico Medicine, a clinical-stage biotech company driven by generative artificial intelligence (AI), announced the initiation of Phase II clinical trials for INS018_055, which becomes the world's first anti-fibrotic small molecule inhibitor discovered through generative AI, that involves a randomized, double-blind, placebo-controlled trial to assess safety, tolerability, pharmacokinetics, and preliminary efficacy over a 12-week oral dosage.
- In October 2023, the US National Science Foundation unveiled a USD 10.9 million investment to promote research aligning AI progress with user safety. The Safe Learning-Enabled Systems program, a collaboration among NSF, Open Philanthropy, & Good Ventures, focuses on supporting fundamental research for the development & implementation of secure computerized learning systems, which includes ensuring safety & resilience in autonomous and generative AI technologies.
Report Details
| Report Characteristics |
| Market Size (2023) |
USD 92.1 Mn |
| Forecast Value (2032) |
USD 406.6 Mn |
| CAGR (2023-2032) |
17.9% |
| Historical Data |
2017 - 2022 |
| Forecast Data |
2023 - 2032 |
| Base Year |
2022 |
| Estimate Year |
2023 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Technology (Generative Adversarial Networks,
Variational Autoencoders, and Reinforcement
Learning), By Application (Drug Discovery and
Development, Medical Imaging, Genomics and
Proteomics, Protein Engineering, and Synthetic
Biology), By End User (Pharmaceutical &
Biotechnology Companies, Healthcare Provider, and
Research Institutions) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
IBM Corp, NVIDIA Corp, DeepMind Technologies Ltd,
Zymergen, Benevolent AI, Insilico Medicine,
Recursion Pharmaceuticals, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Generative Al in Biology Market size is estimated to have a value of USD 92.1 million in 2023
and is expected to reach USD 406.6 million by the end of 2032.
North America has the largest market share for the Global Generative Al in Biology Market with a share
of about 40.2%% in 2023.
Some of the major key players in the Global Generative Al in (IBM Corp, NVIDIA Corp, DeepMind
Technologies Ltd,and many others.
The market is growing at a CAGR of 17.9 percent over the forecasted period.